Edelris Announces Collaboration With Merck Serono in Fragment Based Drug Discovery

01-Oct-2010 - France

Edelris announced that they have signed collaboration with Merck Serono, a division of Merck KGaA, Darmstadt,Germany, aiming at the delivery of innovative and exclusive chemical entities for Fragment-Based Drug Discovery (FBDD).

"We are pleased to be collaborating again with Merck Serono on cutting-edge discovery technologies," said Dr. Jean-Yves Ortholand, CEO of Edelris. "Edelris has acquired a unique expertise in the synthesis of biorelevant innovative fragments maximizing 3D-diversity. Our platform has been developed to explore targeted or diversified spaces aiming at providing fragments with high potential for molecular interactions" added Dr.Didier Roche, VP Strategy and Innovation at Edelris.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances